免疫调节化合物RU 41.740对预防慢性支气管炎患者急性加重的作用。
The effect of RU 41.740, an immune modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis.
作者信息
Bonde J, Dahl R, Edelstein R, Kok-Jensen A, Lazer L, Punakivi L, Seppala A, Soes-Petersen U, Viskum K
出版信息
Eur J Respir Dis. 1986 Oct;69(4):235-41.
The effect of Biostim (RU 41.740), a new non-specific immune modulator, in reducing the number of acute exacerbations in patients with chronic bronchitis, was examined. One hundred and ninety-eight patients with chronic bronchitis stages 2 and 3 entered the study, which was conducted as a multicenter, double-blind, parallel three-group, placebo-controlled trial. The patients were randomised to placebo, Biostim 2 or 8 mg per day, and received treatment for 1 week every other week for 3 successive months during the winter 1983. A significant (p = 0.005) reduction in the number of acute exacerbations was observed in the patients treated with Biostim 2 mg/day, whereas no effect was observed in the placebo or 8 mg/day group. No serious side-effects were encountered.
对一种新型非特异性免疫调节剂Biostim（RU 41.740）减少慢性支气管炎患者急性加重次数的效果进行了研究。198例2期和3期慢性支气管炎患者参与了该研究，研究采用多中心、双盲、平行三组、安慰剂对照试验。患者被随机分为安慰剂组、每日2毫克或8毫克Biostim组，并在1983年冬季连续3个月每隔一周接受1周的治疗。每日服用2毫克Biostim的患者急性加重次数显著减少（p = 0.005），而安慰剂组或每日8毫克组未观察到效果。未出现严重副作用。
Zotero 插件